BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7162464)

  • 61. Activation of deoxycytidine kinase by various nucleoside analogues.
    Spasokoukotskaja T; Sasvári-Székely M; Hullán L; Albertioni F; Eriksson S; Staub M
    Adv Exp Med Biol; 1998; 431():641-5. PubMed ID: 9598144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
    Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
    J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase.
    Shewach DS; Liotta DC; Schinazi RF
    Biochem Pharmacol; 1993 Apr; 45(7):1540-3. PubMed ID: 8385948
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.
    Heinemann V; Plunkett W
    Biochem Pharmacol; 1989 Nov; 38(22):4115-21. PubMed ID: 2688654
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release.
    Månsson B; Geborek P; Saxne T; Björnsson S
    Ann Rheum Dis; 1990 Aug; 49(8):594-7. PubMed ID: 2396864
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alterations in differentiation and pyrimidine pathway enzymes in 5-azacytidine resistant variants of a myoblast line.
    Ng SK; Rogers J; Sanwal BD
    J Cell Physiol; 1977 Feb; 90(2):361-47. PubMed ID: 65357
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
    Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
    Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advantages and disadvantages of cytidine deamination.
    Cascalho M
    J Immunol; 2004 Jun; 172(11):6513-8. PubMed ID: 15153462
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enzymology of cytosine arabinoside.
    Cheng YC; Capizzi RL
    Med Pediatr Oncol; 1982; 10 Suppl 1():27-31. PubMed ID: 7162464
    [No Abstract]   [Full Text] [Related]  

  • 71. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
    Chabot GG; Bouchard J; Momparler RL
    Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
    [No Abstract]   [Full Text] [Related]  

  • 72. Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase.
    Mejer J; Mortensen BT
    Adv Exp Med Biol; 1989; 253B():335-9. PubMed ID: 2558539
    [No Abstract]   [Full Text] [Related]  

  • 73. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia.
    Colly LP; Peters WG; Richel D; Arentsen-Honders MW; Starrenburg CW; Willemze R
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):257-61. PubMed ID: 3035720
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Deamination rates of 1-beta-D-arabinofuranosylcytosine, deoxycytidine and 5-methyl-2'-deoxycytidine in seven hematopoietic cell lines.
    Jekunen A
    Med Biol; 1987; 65(4):203-8. PubMed ID: 3437781
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.